Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sosei Group ( (JP:4565) ) just unveiled an update.
Nxera Pharma reported significant advancements in its strategic focus on obesity and metabolic diseases during the third quarter of 2025, highlighted by the launch of a proprietary pipeline led by an oral GLP-1 agonist. The company also achieved key milestones in its collaborations, including a $10 million payment from AbbVie for neurological disease research, and presented promising Phase 1 trial results for its cancer immunotherapy candidate. Despite these operational successes, Nxera experienced a financial downturn with increased R&D expenses and a net loss of JPY 4,809 million, reflecting the company’s investment in future growth and the impact of a weaker yen.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen883.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-powered biopharmaceutical company focused on developing new specialty medicines to address unmet medical needs in Japan and globally.
Average Trading Volume: 726,978
Technical Sentiment Signal: Sell
Current Market Cap: Yen81.9B
For an in-depth examination of 4565 stock, go to TipRanks’ Overview page.